Format

Send to

Choose Destination
See comment in PubMed Commons below
Blood. 2013 Jun 6;121(23):4627-34. doi: 10.1182/blood-2013-02-427641. Epub 2013 Apr 8.

SF3B1 mutations in chronic lymphocytic leukemia.

Author information

1
Cancer Vaccine Center, Dana-Farber Cancer Institute, Boston, MA 02115, USA

Abstract

SF3B1 is a critical component of the splicing machinery, which catalyzes the removal of introns from precursor messenger RNA (mRNA). Next-generation sequencing studies have identified mutations in SF3B1 in chronic lymphocytic leukemia (CLL) at high frequency. In CLL, SF3B1 mutation is associated with more aggressive disease and shorter survival, and recent studies suggest that it can be incorporated into prognostic schema to improve the prediction of disease progression. Mutations in SF3B1 are predominantly subclonal genetic events in CLL, and hence are likely later events in the progression of CLL. Evidence of altered pre-mRNA splicing has been detected in CLL cases with SF3B1 mutations. Although the causative link between SF3B1 mutation and CLL pathogenesis remains unclear, several lines of evidence suggest SF3B1 mutation might be linked to genomic stability and epigenetic modification.

PMID:
23568491
PMCID:
PMC3674664
DOI:
10.1182/blood-2013-02-427641
[Indexed for MEDLINE]
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for HighWire Icon for PubMed Central
    Loading ...
    Support Center